Arrowhead Research Corp. (NASDAQ:ARWR) shares rose 2.9% during trading on Friday . The company traded as high as $5.75 and last traded at $5.74, with a volume of 108,336 shares changing hands. The stock had previously closed at $5.58.

A number of analysts have recently weighed in on ARWR shares. Vetr upgraded Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 target price for the company in a research report on Wednesday, April 20th. Chardan Capital started coverage on Arrowhead Research Corp. in a research report on Thursday, May 19th. They set a “buy” rating and a $12.00 target price for the company. Finally, Jefferies Group reiterated a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $10.27.

The firm has a 50 day moving average of $5.71 and a 200 day moving average of $5.04. The firm’s market capitalization is $338.77 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Analysts predict that Arrowhead Research Corp. will post ($1.40) earnings per share for the current year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.